---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-018696"
form_type: "8-K"
ticker: "LNSR"
cik: "0001320350"
company_name: "LENSAR, Inc."
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:16:47.828909+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# LENSAR Q1 2022 revenue $9.3M (+33% YoY); net loss $6.7M; ALLY 510(k) under FDA review

## Summary
- Total revenue $9.3M, up 33% from $7.0M in Q1 2021; 89% from recurring sources.
- Procedure volume 38,901, up 38% YoY; product, lease, and service revenue all increased.
- Net loss $6.7M ($0.67 per share) vs $5.2M ($0.56) in Q1 2021; R&D expense rose 74% to $4.8M due to ALLY development.
- FDA accepted 510(k) for ALLY Adaptive Cataract Treatment System; launch anticipated in 2022 if cleared.
- Adjusted EBITDA was ($4.2)M vs ($2.2)M in Q1 2021; stock-based comp $1.6M.

## SEC filing metadata
- accession: 0001564590-22-018696
- form_type: 8-K
- ticker: LNSR
- cik: 0001320350
- company_name: LENSAR, Inc.
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1320350/000156459022018696/0001564590-22-018696-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1320350/000156459022018696/lnsr-8k_20220509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-018696
- JSON: https://secwatch.observer/filing/0001564590-22-018696.json
- Plain text: https://secwatch.observer/filing/0001564590-22-018696.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.